John W. Park

16.2k citations

130 papers · 11.2k indexed · 4 hit papers · h-index 55

Impact in

Biomaterials top 0.1%
- Nanoparticle-Based Drug Delivery
Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis

Papers in

Oncology 76
- HER2/EGFR in Cancer Research 32
- Cancer Cells and Metastasis 27
- Cancer Treatment and Pharmacology 10
Biomaterials 34
- Nanoparticle-Based Drug Delivery 34

Co-authors: Dmitri B. Kirpotin Keelung Hong Daryl C. Drummond Christopher C. Benz Charles O. Noble James D. Marks Christoph Mamot Ulrik B. Nielsen
Journals: Journal of Clinical Oncology (13 papers)Clinical Cancer Research (10 papers)Breast Cancer Research and Treatment (9 papers)Cancer Research (7 papers)Cancer Letters (3 papers)
Partner nations: United States Hungary China

In The Last Decade

John W. Park

129 papers receiving 10.9k citations

Hit Papers

align trajectories log scale

The cancer glycocalyx mechanically primes integrin-mediated growth and survival 2014 · 520 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 Nature
2006 Cancer Research
2002 PubMed
1992 Science

Peers

Countries citing papers authored by John W. Park

Since Specialization

Citations

This map shows the geographic impact of John W. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John W. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John W. Park more than expected).

Fields of papers citing papers by John W. Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John W. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John W. Park. The network helps show where John W. Park may publish in the future.

Co-authorship network

The 25 scholars most cited alongside John W. Park, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John W. Park Line = papers co-authored together John W. Park links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series The Oncologist ·Amanda S. Bluem, Francis Wright, 齊學平, A. Jo Chien, Jasmine Wong, John W. Park, Amie Blanco, Katherine Van Loon, Chloé E. Atreya	2024	1
2	Clinical Significance of Circulating Tumor Cells in Hormone Receptor–positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab Clinical Cancer Research ·Mark Jesus M. Magbanua, Oleksandr Savenkov, Erik Asmus, Karla V. Ballman, Janet H. Scott, John W. Park, Maura N. Dickler, Ann H. Partridge, Lisa A. Carey, Eric P. Winer, Hope S. Rugo	2020	19
3	Synchronous Detection of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow Predicts Adverse Outcome in Early Breast Cancer Clinical Cancer Research ·Mark Jesus M. Magbanua, Christina Yau, Denise M. Wolf, Jin Sun Lee, Steve M. Zinder, Janet H. Scott, T Versluys, E. Shelley Hwang, Michael Alvarado, Cheryl A. Ewing, Amy L. Delson, Laura J. van’t Veer, Laura J. Esserman, John W. Park	2019	21
4	Expanded Genomic Profiling of Circulating Tumor Cells in Metastatic Breast Cancer Patients to Assess Biomarker Status and Biology Over Time (CALGB 40502 and CALGB 40503, Alliance) Clinical Cancer Research ·Mark Jesus M. Magbanua, Hope S. Rugo, Denise M. Wolf, 晏铭胡, Ritu Roy, Francieli Mognon, Eduardo V. Sosa, Janet H. Scott, Jin Sun Lee, Brandelyn N. Pitcher, Terry Hyslop, William T. Barry, Steven J. Isakoff, Maura N. Dickler, Laura van’t Veer, John W. Park	2018	36
5	Enrichment and Detection of Circulating Tumor Cells and Other Rare Cell Populations by Microfluidic Filtration Advances in experimental medicine and biology ·Michael J. Pugia, Mark Jesus M. Magbanua, John W. Park	2017	5
6	Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer Breast Cancer Research and Treatment ·Jin Sun Lee, Michelle Melisko, Mark Jesus M. Magbanua, Аліна Олексіївна Кулик, Janet H. Scott, Hope S. Rugo, John W. Park	2015	55
7	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers Clinical Cancer Research ·Mark Jesus M. Magbanua, Lisa A. Carey, Amy DeLuca, Jimmy Hwang, Janet H. Scott, Mothaffar F. Rimawi, Erica L. Mayer, P. Kelly Marcom, Minetta C. Liu, Francisco J. Esteva, John W. Park, Hope S. Rugo	2014	32
8	Molecular Profiling of Tumor Cells in Cerebrospinal Fluid and Matched Primary Tumors from Metastatic Breast Cancer Patients with Leptomeningeal Carcinomatosis Cancer Research ·Mark Jesus M. Magbanua, Michelle Melisko, Ritu Roy, Eduardo V. Sosa, 晏铭胡, Аліна Олексіївна Кулик, Robert Donald Habbit, NA Caracas-Portilla, Alfred Au, Janet H. Scott, John W. Park	2013	52
9	Genomic Profiling of Isolated Circulating Tumor Cells from Metastatic Breast Cancer Patients Cancer Research ·Mark Jesus M. Magbanua, Eduardo V. Sosa, Ritu Roy, Robert Donald Habbit, Janet H. Scott, Adam B. Olshen, Dan Pinkel, Hope S. Rugo, John W. Park	2012	78
10	Experimental Radionuclide Therapy of HER2-Expressing Xenografts Using Two-Step Targeting Nuclisome Particles Journal of Nuclear Medicine ·Lars Gedda, A. T. Guld, Hans Lundqvist, John W. Park, Katarina Edwards	2012	8
11	Disseminated tumor cells: the method is the message Breast Cancer Research and Treatment ·John W. Park	2010	6
12	Proteasome-Regulated ERBB2 and Estrogen Receptor Pathways in Breast Cancer Molecular Pharmacology ·Corina Marx, Christina Yau, Surita Banwait, Yamei Zhou, Gary K. Scott, Byron Hann, John W. Park, Christopher C. Benz	2007	22
13	Antibody Targeting of Long-Circulating Lipidic Nanoparticles Does Not Increase Tumor Localization but Does Increase Internalization in Animal Models Cancer Research ·Dmitri B. Kirpotin, Daryl C. Drummond, Yi Shao, M R Shalaby, Keelung Hong, Ulrik B. Nielsen, James D. Marks, Christopher C. Benz, John W. Park Hit paper breakdown →	2006	863
14	Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines Cancer Letters ·Maria‐Magdalena Mocanu, Thomnas Vallianippuram, T. Du Pre, Péter Nagy, Zsolt Sebestyén, Jorma Isola, József Tı́már, John W. Park, György Vereb, János Szöllõsi	2005	36
15	Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging Brain Research Protocols ·Michal T. Krauze, Tracy R. McKnight, Yoji Yamashita, John R. Bringas, Charles O. Noble, Ryuta Saito, Karsten Geletneky, John Forsayeth, Mitchel S. Berger, Pamela Jackson, John W. Park, Krystof S. Bankiewicz	2005	77
16	Future directions of liposome- and immunoliposome-based cancer therapeutics Seminars in Oncology ·John W. Park, Christopher C. Benz, Francis J. Martin	2004	167
17	Anti-HER2 Immunoliposomes Clinical Cancer Research ·John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, José Baselga, Yvonne Shao, Ulrik B. Nielsen, James D. Marks, Dan H. Moore, Demetrios Papahadjopoulos, Christopher C. Benz	2002	10
18	Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. PubMed ·John W. Park, Keelung Hong, Dmitri B. Kirpotin, Gail Colbern, Refaat Shalaby, José Baselga, Yvonne Shao, Ulrik B. Nielsen, James D. Marks, Dan H. Moore, Demetrios Papahadjopoulos, Christopher C. Benz Hit paper breakdown →	2002	518
19	Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2 Journal of Cell Science ·Péter Nagy, György Vereb, Zsolt Sebestyén, Gábor Horváth, Stephen J. Lockett, Sándor Damjanovich, John W. Park, Thomas M. Jovin, János Szöllõsi	2002	150
20	Cationic Liposomes Coated with Polyethylene Glycol As Carriers for Oligonucleotides Journal of Biological Chemistry ·Olivier Meyer, Dmitri B. Kirpotin, Keelung Hong, Brigitte Sternberg, John W. Park, Martin C. Woodle, Demetrios Papahadjopoulos	1998	165

About John W. Park

John W. Park is a scholar working on Oncology, Biomaterials, Radiology, Nuclear Medicine and Imaging, Cancer Research and Genetics, having authored 130 papers that have together received 11.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (38 papers), Nanoparticle-Based Drug Delivery (34 papers), HER2/EGFR in Cancer Research (32 papers), Cancer Cells and Metastasis (27 papers), Cancer Genomics and Diagnostics (22 papers), RNA Interference and Gene Delivery (14 papers), Glycosylation and Glycoproteins Research (12 papers) and Cancer Treatment and Pharmacology (10 papers). The work is most often cited by research in Biomaterials (3.5k citations), Oncology (3.3k citations), Radiology, Nuclear Medicine and Imaging (2.2k citations), Cancer Research (1.3k citations) and Molecular Biology (5.6k citations). John W. Park has collaborated with scholars based in United States, Hungary and China. Frequent co-authors include Dmitri B. Kirpotin, Keelung Hong, Daryl C. Drummond, Christopher C. Benz, Charles O. Noble, James D. Marks, Christoph Mamot, Ulrik B. Nielsen, Demetrios Papahadjopoulos and Krystof S. Bankiewicz. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Breast Cancer Research and Treatment, Cancer Research and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact